Literature DB >> 33014395

Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review.

Lisa R Rogers1, Quinn T Ostrom2, Julia Schroer3, Jaime Vengoechea4, Li Li3, Stanton Gerson3, Charles J Nock3,5, Mitchell Machtay3,6, Warren Selman1,3, Simon Lo7, Andrew E Sloan1,3,8, Jill S Barnholtz-Sloan3,9.   

Abstract

BACKGROUND: Metabolic syndrome is identified as a risk factor for the development of several systemic cancers, but its frequency among patients with glioblastoma and its association with clinical outcomes have yet to be determined. The aim of this study was to investigate metabolic syndrome as a risk factor for and affecting survival in glioblastoma patients.
METHODS: A retrospective cohort study, consisting of patients with diagnoses at a single institution between 2007 and 2013, was conducted. Clinical records were reviewed, and clinical and laboratory data pertaining to 5 metabolic criteria were extrapolated. Overall survival was determined by time from initial surgical diagnosis to date of death or last follow-up.
RESULTS: The frequency of metabolic syndrome among patients diagnosed with glioblastoma was slightly greater than the frequency of metabolic syndrome among the general population. Within a subset of patients (n = 91) receiving the full schedule of concurrent radiation and temozolomide and adjuvant temozolomide, median overall survival was significantly shorter for patients with metabolic syndrome compared with those without. In addition, the presence of all 5 elements of the metabolic syndrome resulted in significantly decreased median survival in these patients.
CONCLUSIONS: We identified the metabolic syndrome at a slightly higher frequency in patients with diagnosed glioblastoma compared with the general population. In addition, metabolic syndrome with each of its individual components is associated with an overall worse prognosis in patients receiving the standard schedule of radiation and temozolomide after adjustment for age.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  glioblastoma; hyperglycemia; metabolic syndrome; obesity; survival

Year:  2020        PMID: 33014395      PMCID: PMC7516096          DOI: 10.1093/nop/npaa011

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  36 in total

1.  Links between private habits, psychological stress and brain cancer: a case-control pilot study in France.

Authors:  Cécilia Cabaniols; Roch Giorgi; Olivier Chinot; Nabila Ferahta; Valérie Spinelli; Philippe Alla; Maryline Barrie; Marie-Pascale Lehucher-Michel
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

2.  Diabetes, use of antidiabetic drugs, and the risk of glioma.

Authors:  Corinna Seliger; Cristian Ricci; Christoph R Meier; Michael Bodmer; Susan S Jick; Ulrich Bogdahn; Peter Hau; Michael F Leitzmann
Journal:  Neuro Oncol       Date:  2015-06-20       Impact factor: 12.300

3.  Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study.

Authors:  Michael Edlinger; Susanne Strohmaier; Håkan Jonsson; Tone Bjørge; Jonas Manjer; Wegene T Borena; Christel Häggström; Anders Engeland; Steinar Tretli; Hans Concin; Gabriele Nagel; Randi Selmer; Dorthe Johansen; Tanja Stocks; Göran Hallmans; Pär Stattin; Hanno Ulmer
Journal:  J Hypertens       Date:  2012-02       Impact factor: 4.844

4.  Hypertension as a risk factor for glioma? Evidence from a population-based study of comorbidity in glioma patients.

Authors:  M P W A Houben; W J Louwman; C C Tijssen; J L J M Teepen; C M Van Duijn; J W W Coebergh
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

5.  Prediagnostic body weight and survival in high grade glioma.

Authors:  Erin M Siegel; L Burton Nabors; Reid C Thompson; Jeffrey J Olson; James E Browning; Melissa H Madden; Gang Han; Kathleen M Egan
Journal:  J Neurooncol       Date:  2013-05-11       Impact factor: 4.130

6.  Height, body mass index, and physical activity in relation to glioma risk.

Authors:  Steven C Moore; Preetha Rajaraman; Robert Dubrow; Amy S Darefsky; Corinna Koebnick; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

7.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

8.  The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.

Authors:  Markus K H Wiedmann; Cathrine Brunborg; Antonio Di Ieva; Kristina Lindemann; Tom B Johannesen; Lars Vatten; Eirik Helseth; John A Zwart
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

9.  Family history of cancer in benign brain tumor subtypes versus gliomas.

Authors:  Quinn T Ostrom; Christopher McCulloh; Yanwen Chen; Karen Devine; Yingli Wolinsky; Perica Davitkov; Sarah Robbins; Rajesh Cherukuri; Ashokkumar Patel; Rajnish Gupta; Mark Cohen; Jaime Vengoechea Barrios; Cathy Brewer; Cathy Schilero; Kathy Smolenski; Mary McGraw; Barbara Denk; Theresa Naska; Frances Laube; Ruth Steele; Dale Greene; Alison Kastl; Susan Bell; Dina Aziz; E A Chiocca; Christopher McPherson; Ronald Warnick; Gene H Barnett; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Front Oncol       Date:  2012-02-28       Impact factor: 6.244

Review 10.  Metabolic syndrome and risk of cancer: a systematic review and meta-analysis.

Authors:  Katherine Esposito; Paolo Chiodini; Annamaria Colao; Andrea Lenzi; Dario Giugliano
Journal:  Diabetes Care       Date:  2012-11       Impact factor: 19.112

View more
  3 in total

1.  Metabolics risk factors in a New Zealand glioblastoma cohort.

Authors:  Eileen J McManus; Chris Frampton; Alvin Tan; Matthew C L Phillips
Journal:  Neurooncol Pract       Date:  2021-11-12

2.  Hydrogen sulfide operates as a glioblastoma suppressor and is lost under high fat diet.

Authors:  Daniel J Silver; Justin D Lathia; Christopher Hine
Journal:  Mol Cell Oncol       Date:  2021-09-16

Review 3.  PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging.

Authors:  Michael R Duggan; Michael Weaver; Kamel Khalili
Journal:  Aging (Albany NY)       Date:  2021-01-05       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.